City of Hope National Medical Center Program

The Hematology and Medical Oncology Fellowship Program at City of Hope is a prestigious and comprehensive training experience designed to develop the next generation of clinician-scientists dedicated to patient care in the fields of hematology and oncology. As a National Cancer Institute-designated comprehensive cancer center, City of Hope is committed to excellence in research, medical education, and patient-directed care, providing a robust environment for future leaders in the field.

The fellowship spans three years and admits four fellows annually, combining 18 months of intensive clinical training with 18 months of protected research time. This dual focus allows fellows to gain in-depth clinical knowledge and the opportunity to engage in innovative research initiatives within hematology and oncology, ultimately preparing them for a rewarding career.

Program Structure

The fellowship structure comprises a diverse range of clinical rotations and research opportunities. The clinical blocks include the full spectrum of benign and malignant hematology and medical oncology, complemented by electives in related areas such as supportive care, surgical oncology, transfusion medicine, radiology, and cancer genetics. Benign hematology training features didactics and consult blocks, as well as away rotations at partner institutions including Harbor-UCLA Medical Center and Children’s Hospital Los Angeles. A robust didactic curriculum supports fellows' education, ensuring a well-rounded understanding of both clinical practice and underlying scientific principles 1.

Curriculum and Rotations

Fellows partake in an expansive clinical curriculum during their fellowship, which includes a longitudinal experience with malignancies and blood disorders, as well as focused training in relevant subspecialties. Rotations provide hands-on experience treating a patient population with diverse hematologic and oncologic conditions, which is fundamental to developing clinical competence and confidence 2.

Research Opportunities

In terms of research, the fellowship prioritizes scientific inquiry with dedicated months for fellows to engage in laboratory and clinical research projects. City of Hope's strong emphasis on investigational therapies, particularly in cancer treatment, offers fellows the chance to contribute to groundbreaking research that may improve patient outcomes and advance the field 3.

Faculty and Mentorship

The faculty at City of Hope consists of leading experts in hematology and oncology, providing fellows with unparalleled mentorship and guidance throughout their training. The collaborative environment encourages fellows to explore various career pathways within academia, clinical practice, and research 4.

Competitiveness and Application Requirements

Admission to the Hematology and Medical Oncology Fellowship is highly competitive. Applicants must have completed an ACGME-accredited internal medicine residency and possess an MD degree. Additional requirements include a curriculum vitae, personal statement, three letters of recommendation (one from the program director), and USMLE transcript documentation. The program closely collaborates with ERAS for application submissions 5.

Visa Support

City of Hope also provides visa support to international medical graduates, sponsoring J-1 and H-1B visas for eligible candidates, ensuring that capable applicants from diverse backgrounds have the opportunity to join the program and enrich the fellowship experience with their unique perspectives 6.

Unique Aspects and Fellow Engagement

The program goes beyond clinical training by facilitating a humane and supportive atmosphere through multiple special events such as Schwartz Rounds and interdisciplinary conferences focused on patient care challenges. Fellows participate actively in a community that prioritizes well-being and collaboration, emphasizing the program's commitment to producing compassionate and skilled physicians who are not only experts in treatment but also advocates for their patients 7.